GlassScriptPhysician profile
Kenneth J Galang
NPI 1376552661
$2,245.09
in general payments reported to CMS, 2019-2025
31 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $401 · 2021: $479 · 2022: $277 · 2023: $247 · 2024: $340 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $462.72 | 2019-2025 | Xtampza |
| Abbvie INC. | $363.84 | 2021-2025 | |
| Pfizer INC. | $160.53 | 2019-2024 | |
| Scilex Pharmaceuticals INC. | $159.82 | 2019-2022 | |
| Forte Bio-Pharma LLC | $109.45 | 2020-2024 | Prolate, Nalocet |
| Allergan, INC. | $101.35 | 2020 | |
| Idorsia Pharmaceuticals US INC | $88.68 | 2022-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.07 | 2019-2025 | Relistor |
| Si-Bone, INC. | $73.88 | 2022-2024 | |
| Tonix Medicines, INC. | $67.35 | 2025 | Tonmya |
| Novartis Pharmaceuticals Corporation | $55.15 | 2019-2021 | |
| Horizon Therapeutics Plc | $43.88 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $43.86 | 2023 | Onpattro |
| Merck Sharp & Dohme LLC | $42.75 | 2022-2023 | Belsomra |
| Sentynl Therapeutics, INC. | $42.03 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $41.76 | 2019 | |
| Ibsa Pharma INC. | $31.66 | 2020-2021 | |
| Lilly USA, LLC | $30.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $29.02 | 2023 | Seglentis |
| Clarus Therapeutics INC. | $24.41 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.09 | 2021 | |
| Eisai INC. | $22.69 | 2021 | |
| Hikma Pharmaceuticals USA | $21.28 | 2022 | |
| Lundbeck LLC | $18.67 | 2025 | Vyepti |
| Redhill Biopharma INC. | $16.74 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.74 | 2020 | |
| Almatica Pharma LLC | $16.46 | 2023 | Gralise |
| Fidia Pharma USA INC. | $16.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.42 | 2019 | |
| Radius Health, INC. | $13.01 | 2021 | |
| Pernix Therapeutics Holdings, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Galang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.